These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 21415214)

  • 1. Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies.
    Weiss GJ; Infante JR; Chiorean EG; Borad MJ; Bendell JC; Molina JR; Tibes R; Ramanathan RK; Lewandowski K; Jones SF; Lacouture ME; Langmuir VK; Lee H; Kroll S; Burris HA
    Clin Cancer Res; 2011 May; 17(9):2997-3004. PubMed ID: 21415214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.
    Ganjoo KN; Cranmer LD; Butrynski JE; Rushing D; Adkins D; Okuno SH; Lorente G; Kroll S; Langmuir VK; Chawla SP
    Oncology; 2011; 80(1-2):50-6. PubMed ID: 21625179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.
    Papadopoulos KP; Goel S; Beeram M; Wong A; Desai K; Haigentz M; Milián ML; Mani S; Tolcher A; Lalani AS; Sarantopoulos J
    Clin Cancer Res; 2008 Nov; 14(21):7110-5. PubMed ID: 18981010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of pazopanib plus TH-302 in advanced solid tumors.
    Riedel RF; Meadows KL; Lee PH; Morse MA; Uronis HE; Blobe GC; George DJ; Crawford J; Niedzwiecki D; Rushing CN; Arrowood CC; Hurwitz HI
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):611-619. PubMed ID: 28238078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A first-in-human study of conatumumab in adult patients with advanced solid tumors.
    Herbst RS; Kurzrock R; Hong DS; Valdivieso M; Hsu CP; Goyal L; Juan G; Hwang YC; Wong S; Hill JS; Friberg G; LoRusso PM
    Clin Cancer Res; 2010 Dec; 16(23):5883-91. PubMed ID: 20947515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.
    Badar T; Handisides DR; Benito JM; Richie MA; Borthakur G; Jabbour E; Harutyunyan K; Konoplev S; Faderl S; Kroll S; Andreeff M; Pearce T; Kantarjian HM; Cortes JE; Thomas DA; Konopleva M
    Am J Hematol; 2016 Aug; 91(8):800-5. PubMed ID: 27169385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.
    Patnaik A; Rowinsky EK; Villalona MA; Hammond LA; Britten CD; Siu LL; Goetz A; Felton SA; Burton S; Valone FH; Eckhardt SG
    Clin Cancer Res; 2002 Jul; 8(7):2142-8. PubMed ID: 12114414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
    Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
    Gordon MS; Sweeney CS; Mendelson DS; Eckhardt SG; Anderson A; Beaupre DM; Branstetter D; Burgess TL; Coxon A; Deng H; Kaplan-Lefko P; Leitch IM; Oliner KS; Yan L; Zhu M; Gore L
    Clin Cancer Res; 2010 Jan; 16(2):699-710. PubMed ID: 20068101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs.
    Hunter FW; Young RJ; Shalev Z; Vellanki RN; Wang J; Gu Y; Joshi N; Sreebhavan S; Weinreb I; Goldstein DP; Moffat J; Ketela T; Brown KR; Koritzinsky M; Solomon B; Rischin D; Wilson WR; Wouters BG
    Cancer Res; 2015 Oct; 75(19):4211-23. PubMed ID: 26297733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys.
    Jung D; Lin L; Jiao H; Cai X; Duan JX; Matteucci M
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):643-54. PubMed ID: 21964906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule.
    Awada A; Punt CJ; Piccart MJ; Van Tellingen O; Van Manen L; Kerger J; Groot Y; Wanders J; Verweij J; Wagener DJ
    Br J Cancer; 1999 Mar; 79(9-10):1454-61. PubMed ID: 10188890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors.
    Clark JW; Eder JP; Ryan D; Lathia C; Lenz HJ
    Clin Cancer Res; 2005 Aug; 11(15):5472-80. PubMed ID: 16061863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
    Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
    Mita MM; Mita AC; Chu QS; Rowinsky EK; Fetterly GJ; Goldston M; Patnaik A; Mathews L; Ricart AD; Mays T; Knowles H; Rivera VM; Kreisberg J; Bedrosian CL; Tolcher AW
    J Clin Oncol; 2008 Jan; 26(3):361-7. PubMed ID: 18202410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954.
    Chung-Faye G; Palmer D; Anderson D; Clark J; Downes M; Baddeley J; Hussain S; Murray PI; Searle P; Seymour L; Harris PA; Ferry D; Kerr DJ
    Clin Cancer Res; 2001 Sep; 7(9):2662-8. PubMed ID: 11555577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors.
    Shimizu T; Okamoto I; Tamura K; Satoh T; Miyazaki M; Akashi Y; Ozaki T; Fukuoka M; Nakagawa K
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):243-50. PubMed ID: 19479254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery).
    Graham JS; Plummer R; McCoy C; Kowal K; Wiesinger H; Detjen K; Calvert H; Wiedenmann B; Cassidy J
    Eur J Cancer; 2008 Oct; 44(15):2162-8. PubMed ID: 18653327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect.
    Hong CR; Wilson WR; Hicks KO
    Neoplasia; 2019 Feb; 21(2):159-171. PubMed ID: 30591421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.